Studio Prospettico sulla Gastroplastica Endoscopica a Manicotto (ESG) per l'Obesità (EGO-Trial)
Studio Prospettico sulla Gastroplastica Endoscopica a Manicotto (ESG) per l'Obesità
EGO-Trial is the first multicenter study in France which aims to evaluate the efficacy of Endoscopic Sleeve Gastroplasty (ESG) in patients with obesity. This project fills a critical national gap by providing real-world, multicentric data from diverse French healthcare settings, offering insight into the safety, efficacy, and variability of ESG practices across institutions
The project is expected to generate robust, multicentric clinical evidence on the safety and efficacy of ESG in patients with obesity within the French healthcare context.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Obesity, particularly morbid obesity, is a major public health issue in France. According to the latest data from the ObÉpi-Roche 2020 survey, more than 17% of French adults are obese. Obesity is a well-established risk factor for many chronic diseases such as type 2 diabetes, cardiovascular disease, high blood pressure (HBP), musculoskeletal disorders, certain cancers, and non-alcoholic steatohepatitis (NASH). It is associated with a significant reduction in life expectancy and represents a direct cost estimated at more than €5 billion per year for the French healthcare system.
While bariatric surgery (particularly sleeve gastrectomy and gastric bypass) remains the gold standard treatment for severe obesity, it is invasive, costly, and only offered to a minority of patients (less than 10% of eligible patients). In addition, certain medical contraindications, refusal of surgery, and waiting times limit access to this treatment.
Endoscopic sleeve gastroplasty ("Endosleeve"). Endoscopic sleeve gastroplasty (ESG) is an innovative, non-surgical, natural procedure that reduces stomach volume without resection or anastomosis. It has shown promising results in terms of weight loss, metabolic improvement, and safety, while being reversible and reproducible. The MERIT randomized controlled trial in USA (JAMA, 2022) demonstrated an average weight loss of 13.6% of total body weight at 12 months (vs. 0.8% in the control group), as well as a significant improvement in comorbidities such as type 2 diabetes and hypertension.
Hypothesis and objective of the study The hypothesis of this study is that ESG, when performed under routine care conditions in the United States, leads to significant and sustainable weight loss, associated with an improvement in comorbidities, with a favorable safety profile. The main objective of this project is therefore to evaluate, on a national scale, the clinical efficacy, safety, and procedural variability of ESG through a multicenter real-world cohort.
To date, no large-scale French study has analyzed the results of ESG in real-world settings. This hinders its integration into national healthcare pathways, its reimbursement by the French national health insurance system, and its wider adoption by the medical community. The question raised-the rigorous evaluation of ESG in the French context-therefore remains unanswered.
This project aims to generate robust data representative of the national clinical reality in order to support the supervised development of ESG. Expected outcomes include the publication of scientific articles in peer-reviewed journals, the presentation of results at international conferences, contributions to health technology assessment work, and the establishment of a national registry of endoscopic gastroplasty. This work could represent a major advance in the therapeutic arsenal for obesity, supporting the integration of ESG as a recognized, validated, and reimbursed option in French healthcare pathways.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Armelle TAKEDA
- Numero di telefono: 0033 390 413608
- Email: armelle.takeda@ihu-strasbourg.eu
Backup dei contatti dello studio
- Nome: Clinical Research Team
- Email: rc-ihu@ihu-strasbourg.eu
Luoghi di studio
-
-
-
Aix-en-Provence, Francia
- Reclutamento
- Hôpital Privé de Provence
-
Contatto:
- Hugues SEBBAG
- Numero di telefono: 0033 4 42 21 12 11
- Email: hsebbag.ppr@hotmail.fr
-
Besançon, Francia
- Non ancora reclutamento
- Polyclinique de Franche-Comté
-
Contatto:
- Henry-Alexis MERCOLI
- Numero di telefono: 0033 3 81 41 81 41
- Email: docteur.mercoli@gmail.com
-
Lille, Francia
- Non ancora reclutamento
- Hôpital HURIEZ
-
Contatto:
- Robert CAIAZZO
- Numero di telefono: 0033 3 20 44 42 73
- Email: robert.caiazzo@univ-lille2.fr
-
Lyon, Francia
- Reclutamento
- Clinique de la Sauvegarde
-
Contatto:
- Marie-Cécile BLANCHET
- Numero di telefono: +33 4 37 49 70 10
- Email: blanchet@chirurgien-digestif.com
-
Lyon, Francia
- Reclutamento
- Hospices Civils de Lyon - Hôpital Edourard HERRIOT
-
Contatto:
- Maud ROBERT
- Numero di telefono: 0033 4 72 11 62 61
- Email: Maud.robert@chu-lyon.fr
-
Montpellier, Francia
- Non ancora reclutamento
- Clinique Clémentville
-
Contatto:
- Marta SILVESTRI
- Numero di telefono: 0033 4 67 06 70 00
- Email: docteur.m.silvestri@gmail.com
-
Saint-Etienne, Francia
- Non ancora reclutamento
- Centre Mutualiste de l'Obésité
-
Contatto:
- Pierre BLANC
- Numero di telefono: 0033 4 77 81 82 88
- Email: PBLANC@mutualite-loire.com
-
Saint-Grégoire, Francia
- Non ancora reclutamento
- CHP Saint-Grégoire
-
Contatto:
- Adrien STERKERS
- Numero di telefono: +33 2 99 23 93 10
- Email: asterkers@vivalto-sante.com
-
Strasbourg, Francia
- Reclutamento
- Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil
-
Contatto:
- Silvana PERRETTA
- Numero di telefono: 0033 3 69 55 05 31
- Email: perretta@unistra.fr
-
Sète, Francia
- Reclutamento
- Polyclinique Sainte Thérèse
-
Contatto:
- Thibaut COSTE
- Numero di telefono: 0033 4 67 18 88 20
- Email: thibautcoste@gmail.com
-
Échirolles, Francia
- Non ancora reclutamento
- Clnique des Cèdres
-
Contatto:
- Fabien STENARD
- Numero di telefono: 0033 4 56 58 14 90
- Email: fabien.stenard@cliniquedescedres.com
-
-
-
-
-
Baie-Mahault, Guadalupa
- Non ancora reclutamento
- Clinique les Eaux Claires
-
Contatto:
- Venetia AVENDANO
- Numero di telefono: 0033 5 90 25 95 65
- Email: zulemacu@yahoo.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Adult patients with obesity scheduled for endoscopic gastroplasty
Descrizione
Inclusion Criteria:
- Patients aged 18 to 75 years.
- Patients with a Body Mass Index (BMI) ≥ 30 kg/m².
- Patients who have failed non-surgical weight loss interventions (diet, exercise, pharmacological therapy).
- Patients not eligible for bariatric surgery or does not wish to undergo it.
- Patients who can undergo general anesthesia.
- Patients who are able to participate in all aspects of the study and agree to comply with all study requirements for the entire duration of the study.
- Patients who are able to fully understand the study and are willing to give their consent to participate in the study.
- Patients affiliated with the French social security system.
Exclusion Criteria:
- Patients with contraindications to endoscopic gastroplasty
- Patients with active peptic ulcer disease or significant gastroparesis
- Patients with a history of bariatric, gastric, or esophageal surgery.
- Patients who have started medication in the last 3 months that is known to cause weight gain.
- Patients with a history of uncontrolled, poorly controlled, or suspected eating disorders or psychiatric illness.
- Patients with unstable and precarious health, as determined and assessed by the investigator.
- Patients who are pregnant, breastfeeding, or of childbearing age and not using effective contraception.
- Patients who are currently excluded (as determined by a previous or ongoing study).
- Patients under judicial protection.
- Patients under guardianship, conservatorship or subject to any form of protective supervision
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: CASE_ONLY
- Prospettive temporali: PROSPECTIVE
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Tutti i pazienti adulti con obesità programmati per gastroplastica endoscopica (ESG)
|
Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device which allows for a reduction in stomach volume without resection or anastomosis |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Total Body Weight Loss
Lasso di tempo: At the inclusion and 24 months after procedure
|
Assessment of weight loss in terms of total body weight loss (TBWL, %) 24 months after surgery |
At the inclusion and 24 months after procedure
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Excess weight loss
Lasso di tempo: At the inclusion and 24 months after procedure
|
Assessment of weight loss in terms of excess weight loss (EWL, %) at 24 months post-procedure |
At the inclusion and 24 months after procedure
|
|
Body Mass Index (BMI)
Lasso di tempo: From ESG procedure to the end of participation at 24 months post-procedure
|
Assessment of weight loss in terms of change in Body Mass Index (BMI) at 24 months post-procedure |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Adverse events
Lasso di tempo: From ESG procedure to the end of participation at 24 months post-procedure
|
Rate of minor and major adverse events (e.g., perforation, delayed gastric emptying, reflux symptoms) throughout follow-up for up to 24 months post-procedure |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Comorbidities improvement
Lasso di tempo: From ESG procedure to the end of participation at 24 months post-procedure
|
Assessment of improvement in comorbidities (type 2 diabetes, hypertension, dyslipidemia, sleep apnea) and obesity-related complications over 24 months using the SF-BARI (Swiss-Finnish BARIatric metabolic outcome score) questionnaire: a score developed to evaluate treatment outcomes in obesity management |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Quality of life improvement
Lasso di tempo: From ESG procedure to the end of participation at 24 months post-procedure
|
Assessment of quality of life over 24 months using the GIQLI (Gastrointestinal Quality of Life Index) questionnaire: digestive quality of life score comprising 36 items relating to symptoms, physical status, emotions, social problems, and the effect of medical treatments |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Additional treatments
Lasso di tempo: From ESG procedure to the end of participation at 24 months post-procedure
|
Compilation of additional treatments or revisions required after the procedure |
From ESG procedure to the end of participation at 24 months post-procedure
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Silvana PERRETTA, MD-PhD, Hôpitaux Universitaires de Strasbourg
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 25-004
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .